Drugs / TRDC002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07236112 | Feb → Apr 2026 overdue | prostate cancer | C Ray Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRDC002 | “The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or metastatic prostate cancer.” NCT07236112 ↗ |
| Modality | Diagnostic / imaging agent | “TRDC002 as a PSMA PET tracer” NCT07236112 ↗ |
| Route | Intravenous | “Eligible participants with recurrent or metastatic prostate cancer will be randomized to receive a single dose of either 4 or 6 mCi of TRDC002 intravenously.” NCT07236112 ↗ |